Cancer Trials Ireland wishes to inform members, patients and the wider Irish oncology community that our organisation will continue to operate at full capacity for the duration of the Level 5 restrictions, and beyond. Our organisation has already maximised the remote...

Cancer Trials Ireland is delighted to announce that Professor Seamus O’Reilly has been appointed as Vice-Clinical Lead (VCL) for the organisation. He will take up the position in January 2021. Until then, Cancer Trials Ireland can accept correspondence on behalf...

DASLHiCaP is a new randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer....